Injunction raises questions over regulation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The commercialization of university-based research: Balancing risks and benefits
BMC Medical Ethics Open Access 14 October 2015
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related external links
International Cellular Medicine Society
Regenexx/Regenerative Sciences
Rights and permissions
About this article
Cite this article
Cyranoski, D. FDA challenges stem-cell clinic. Nature 466, 909 (2010). https://doi.org/10.1038/466909a
Published:
Issue date:
DOI: https://doi.org/10.1038/466909a
This article is cited by
-
The commercialization of university-based research: Balancing risks and benefits
BMC Medical Ethics (2015)
-
The global industry for unproven stem cell interventions and stem cell tourism
Tissue Engineering and Regenerative Medicine (2014)
-
Opportunities and barriers to establishing a cell therapy programme in South Africa
Stem Cell Research & Therapy (2013)
-
Recent Developments in Health Care Law: Culture and Controversy
HEC Forum (2013)
-
Stem-cell therapy takes off in Texas
Nature (2012)
